Groupe Oncologie Radiotherapie Tete et Cou clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.

1. Notable

   N'FORCE · Ficerafusp Alfa in Combination With Nivolumab…N'FORCE · Ficerafusp Alfa in Combination With Nivolumab · Platinum-refractory Head and Neck Squamous Cell Carcinoma

   Recruitment opened

   Groupe Oncologie Radiotherapie Tete et Cou·Phase 2· NCT07529873· Registry history of NCT07529873 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.